Turn Therapeutics Inc. (NASDAQ:TTRX) Given Average Rating of “Hold” by Brokerages

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX) have received a consensus recommendation of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $9.00.

A number of research analysts have recently issued reports on the company. Wall Street Zen raised Turn Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. WBB Securities reissued a “sell” rating and issued a $10.00 target price on shares of Turn Therapeutics in a research note on Monday. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Finally, Weiss Ratings cut shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th.

Turn Therapeutics Trading Up 6.8%

NASDAQ TTRX traded up $0.86 during trading hours on Monday, reaching $13.55. The company’s stock had a trading volume of 85,580 shares, compared to its average volume of 55,308. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $26.50. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market cap of $403.80 million and a P/E ratio of -46.14. The firm has a fifty day simple moving average of $9.71 and a 200-day simple moving average of $6.28.

Turn Therapeutics (NASDAQ:TTRX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Equities analysts forecast that Turn Therapeutics will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several large investors have recently modified their holdings of TTRX. Ieq Capital LLC purchased a new position in Turn Therapeutics during the second quarter worth $1,660,000. Millennium Management LLC bought a new position in shares of Turn Therapeutics during the fourth quarter valued at approximately $377,000. Wellington Shields & Co. LLC purchased a new stake in shares of Turn Therapeutics in the fourth quarter worth approximately $259,000. BlackRock Inc. purchased a new stake in Turn Therapeutics in the second quarter worth $282,000. Finally, Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics during the second quarter valued at approximately $242,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.